Detection of minimal residual disease in B lymphoblastic leukemia using viSNE

Cytometry Part B - Clinical Cytometry

Volumn 88, Issue 5, 2015, Pages 294-304

  DiGiuseppe, Joseph A ^a   Tadmor, Michelle D ^b   Pe'Er, Dana ^b  

^a HARTFORD HOSPITAL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

ALL; B lymphoblastic leukemia; flow cytometry; minimal residual disease; viSNE

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUTOANALYSIS; BONE MARROW; CELL POPULATION; DIAGNOSTIC EQUIPMENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VISNE; ALGORITHM; BONE MARROW EXAMINATION; CHEMICALLY INDUCED; IMMUNOLOGY; LABORATORY AUTOMATION; LEUKEMIA, B-CELL; MARKOV CHAIN; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; SIGNAL PROCESSING; TREATMENT OUTCOME;

TUMOR MARKER;

ALGORITHMS; AUTOMATION, LABORATORY; BIOMARKERS, TUMOR; BONE MARROW EXAMINATION; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SIGNAL PROCESSING, COMPUTER-ASSISTED; STOCHASTIC PROCESSES; TREATMENT OUTCOME;

EID: 84939802724     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21252     Document Type: Article

References (34)

1. Campana D,. Minimal residual disease in acute lymphoblastic leukemia. ASH Educ Program Book 2010; 2010: 7-12.
2. Gaipa G, Basso G, Biondi A, Campana D,. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry Part B Clin Cytom 2013; 84B: 359-369.
3. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, et al., Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A children's oncology group study. Blood 2008; 111: 5477-5485.
4. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, et al., Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168-5174.
5. Coustan-Smith E, Campana D,. Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing. Best Pract Res Clin Haematol 2010; 23: 347-358.
6. Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui C-H, et al., New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2011; 117: 6267-6276.
7. DiGiuseppe JA., Acute lymphoblastic leukemia/lymphoma: Diagnosis and minimal residual disease detection by flow cytometric immunophenotyping. In:, Detrick B, Hamilton R, Schmitz J, editors. Manual of Molecular and Clinical Laboratory Immunology, 8th ed. Washington, D.C.: ASM Press (in press).
8. Wood B,. 9color and 10-color flow cytometry in the clinical laboratory. Arch Pathol Lab Med 2006; 130: 680-690.
9. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, Karawajew L, Benetello A, Poetschger U, Husak Z, et al., Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry Part B Clin Cytom 2008; 74: 331-340.
10. Irving J, Jesson J, Virgo P, Case M, Minto L, Eyre L, Noel N, Johansson U, Macey M, Knotts L, et al., Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting. Haematologica 2009; 94: 870-874.
11. Luria D, Rosenthal E, Steinberg D, Kodman Y, Safanaiev M, Amariglio N, Avigad S, Stark B, Izraeli S,. Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytometry Part B Clin Cytom 2010; 78: 365-371.
12. Mejstříková E, Froňková E, Kalina T, Omelka M, Batinic D, Dubravčic K, Pospisilova K, Vaskova M, Luria D, Cheng SH, et al., Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer 2010; 54: 62-70.
13. Aghaeepour N, Finak G, Hoos H, Mosmann TR, Brinkman R, Gottardo R, Scheuermann RH,. Critical assessment of automated flow cytometry data analysis techniques. Nat Methods 2013; 10: 228-238.
14. Chattopadhyay PK, Hogerkorp CM, Roederer M,. A chromatic explosion: The development and future of multiparameter flow cytometry. Immunology 2008; 125: 441-449.
15. Chattopadhyay PK, Roederer M,. Cytometry: Today's technology and tomorrow's horizons. Methods 2012; 57: 251-258.
16. Bendall SC, Simonds EF, Qiu P, El-ad DA, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, et al., Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011; 332: 687-696.
17. Fišer K, Sieger T, Schumich A, Wood B, Irving J, Mejstříková E, Dworzak MN,. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry Part A 2012; 81: 25-34.
18. Van der Maaten L, Hinton G,. Visualizing data using t-SNE. J Mach Learn Res 2008; 9: 85.
19. Amir E-Ad, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, Shenfeld DK, Krishnaswamy S, Nolan GP, Pe'er D,. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol 2013; 31: 545-552.
20. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH,. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98: 2498-2507.
21. Borowitz MJ, Chan JKC., B lymphoblastic leukaemia/lymphoma, not otherwise specified. In:, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. pp 168-170.
22. Borowitz MJ, Chan JKC., B lymphoblastic leukaemia/lymphoma, with recurrent genetic abnormalities. In:, Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. pp 171-175.
23. Vrotsos E, Gorgan M, DiGiuseppe JA,. Detection of small abnormal B-lymphoblast populations at diagnosis of chronic myelogenous leukemia, BCR-abl1+: Incidence, phenotypic features, and clinical implications. Cytometry Part B Clin Cytom (in press).
24. DiGiuseppe JA, Fuller SG, Borowitz MJ,. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: Potential usefulness in minimal residual disease detection. Cytometry Part B Clin Cytom 2009; 76: 150-155.
25. DiGiuseppe JA, Cardinali J,. Improved compensation of the fluorochrome AmCyan using cellular controls. Cytometry Part B Clin Cytom 2011; 80: 191-194.
26. DiGiuseppe JA,. Acute lymphoblastic leukemia: Diagnosis and detection of minimal residual disease following therapy. Clin Lab Med 2007; 27: 533-549.
27. Van der Maaten L., Barnes-Hut-SNE. arXiv 2013; 1301.3342: 1-11.
28. Wood B., Multicolor immunophenotyping: Human immune system hematopoiesis. In:, Darzynkiewicz Z, Roederer M, Tanke HJ, editors. Cytometry, 4th ed.: New Developments. Methods in Cell Biology, Vol. 75. San Diego, CA: Elsevier; 2004. pp. 559-576.
29. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, Faini A, Veltroni M, Husak D, Schumich A, et al., Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry Part B Clin Cytom 2008; 74: 150-155.
30. Soma L, Wood B,. Minimal residual disease testing in acute leukemia. Int J Hematol Oncol 2013; 2: 467-485.
31. Wood BL,. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry Part B Clin Cytom (in press).
32. Walter R, Gooley T, Wood B, Milano F, Fang M, Sorror M, Estey EH, Salter AI, Lansverk E, Chien JW, et al., Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 28: 1-8.
33. Rawstron A, Villamor N, Ritgen M, Böttcher M, Ghia P, Zehnder J, Lozanski G, Colomer D, Moreno C, Geuna M, et al., International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007; 21: 956-964.
34. Rawstron A, Child J, de Tute R, Davies F, Gregory W, Bell S, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, et al., Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the medical research council myeloma IX study. J Clin Oncol 2013; 31: 2540-2547.